SAN LUIS OBISPO, Calif., May 5, 2004 (PRIMEZONE) -- "We changed the name of our NRG division from Neurochemical to 'Nutraceutical Research Group' and acquired the web domain 'www.nutraceuticalresearch.com' to bring the company more inline with industry standard terminology and to make it easier for our customers through the use of search engines to find our planned e-commerce store on the Web," says Michael Smith, Chief Operations Officer for 12 To 20 Plus, Inc. (OTCBB:TTTP).
The term "Nutraceuticals," was coined by Dr. Stephen DeFelice a decade ago to identify "any substance that may be considered a food or part of a food and provides medicinal or health benefits, including the prevention and treatment of disease." (From MedicineNet.com, 22 April 2004)
About 12 to 20 Plus www.12to20plus.com
12 to 20 Plus, Incorporated is a research-based nutraceutical company and a pioneer in the emerging field of specialized nutritional formulas and nutraceuticals. 12 to 20 Plus, Inc. markets highly effective condition-specific dietary supplements containing the most sophisticated combination of extensively researched nutritional elements available. The products are manufactured by FDA-approved labs and do not contain herbs. Instead, the company utilizes potent pharmaceutical grade "amino acids" and important protein constituents that serve as neurotransmitter precursors, membrane stabilizers and enzyme precursors. Some of the proprietary (NRG) products include Anaplex (tm), an antidepressant drug alternative; VisionKare(tm), an advanced supplement for macular degeneration; ChemoKare(tm), a unique combination of extracts designed to treat the side effects of chemotherapy; QuitSystem(r), a neuronutrient supplementation for recovery from alcohol, drugs and smoking. Retail sales in the explosive dietary supplement market are expected to hit $40 billion by year 2007, according to Frost & Sullivan reports.
This release contains forward-looking statements and projections. Such statements and projections are made under the safe harbor provisions of applicable laws and regulations. Any reader should be advised that factors such as development of new capital funding, competition, lack of expert personnel and other factors may materially affect in an adverse manner actual results of operations. Further, any reader of this release should seek competent advice from a registered broker or financial planner prior to investing in shares of the issuer.